Replies to post #2050 on Khiron Life Sciences Corp (KHRNF)

[kahlua]

In answer to your question...Paltry quarterly top line growth. Continuing significant cash burn. Lack of sales or growth updates in UK, Germany and Brazil. Mexico still unofficial. Once they get to a weekly run rate of 1000 script issuance in Columbia that could possibly be a significant inflection point since for now this is primarily an early potential leader play on the Columbia B2C market . At an EV of 30M the stock is relatively cheap but will probably scrape along the bottom here waiting for a catalyst. All imo.